Table 1.
Patient and Tumor Characteristics (N = 38).
| Median | Range | |
|---|---|---|
| Length of Follow-up (months) | 34.5 | 11.5–70.1 |
| Age (years) | 67.0 | 50.0–79.0 |
| Laterality (n,%) | ||
| Right | 17 (44.7) | |
| Left | 21 (55.3) | |
| Biopsy Method (n,%) | ||
| Sentinel Lymph Node Biopsy | 29 (76.3) | |
| Axillary Dissection | 9 (23.7) | |
| T Stage (n,%) | ||
| Tis | 7 (18.4) | |
| T1a | 4 (10.5) | |
| T1b | 11 (28.9) | |
| T1c | 15 (39.5) | |
| T2 | 1 (2.6) | |
| Tumor Size (cm) | 0.9 | 0.0–3.0 |
| Histology (n,%) | ||
| IDC only | 15 (39.5) | |
| DCIS only | 8 (21.1) | |
| Mixed IDC + DCIS | 15 (39.5) | |
| Histologic Grade (n,%) | ||
| 1 | 14 (36.8) | |
| 2 | 19 (50.0) | |
| 3 | 5 (13.2) | |
| ER (n,%) | ||
| Positive | 38 (100.0) | |
| Negative | 0 (0.0) | |
| HER2/neu (n,%) | ||
| Positive | 4 (10.5) | |
| Negative | 34 (89.5) | |
| Hormonal Therapy (n,%) | ||
| Aromatase Inhibitor | 26 (68.4) | |
| Tamoxifen | 3 (7.9) | |
| None | 9 (23.7) | |
| BMI (kg/m2) | 29.3 | 19.6–45.3 |
| Bra Cup Size (n,%) | ||
| A | 2 (5.3) | |
| B | 9 (23.7) | |
| C | 8 (21.1) | |
| D | 9 (23.7) | |
| DD/E | 7 (18.4) | |
| DDD/F | 1 (2.6) | |
| H | 1 (2.6) | |
| Not Reported | 1 (2.6) |
Note: IDC = invasive ductal carcinoma; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HER2/neu = human epidermal growth factor receptor 2; BMI = body mass index.